Gervaso L, Dave H, Khorana AA (2021) Venous and arterial thromboembolism in patients with cancer: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 3(2):173–190

Article  PubMed  PubMed Central  Google Scholar 

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634

Article  CAS  PubMed  Google Scholar 

Connolly GC, Francis CW (2013) Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program 2013:684–691

Article  PubMed  Google Scholar 

Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, Sørensen HT (2010) Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer 103(7):947–953

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809–815

Article  CAS  PubMed  Google Scholar 

Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P (2018) Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers (Basel) 10(10):380

Article  CAS  PubMed  Google Scholar 

Lyman GH (2011) Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 117(7):1334–1349

Article  PubMed  Google Scholar 

Tapson VF (2004) Acute pulmonary embolism. Cardiol Clin 22(3):353–365

Article  PubMed  Google Scholar 

Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O’Connell C, Carrier M (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891–1894

Article  CAS  PubMed  Google Scholar 

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496–520

Article  PubMed  Google Scholar 

Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK (2021) Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):e545–e608

Article  CAS  PubMed  Google Scholar 

Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, Fertrin KY, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Ibrahim I, Kraut E, Leavitt AD, Lee A, Lee JT, Lim M, Mann J, Martin K, McMahon B, Moriarty J, Morton C, Ortel TL, Paschal R, Schaefer J, Shattil S, Siddiqi T, Sudheendra D, Williams E, Hollinger L, Nguyen MQ (2021) Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(10):1181–1201

PubMed  Google Scholar 

Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K (2023) Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol 34(5):452–467

Article  CAS  PubMed  Google Scholar 

Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, Nishimoto Y, Sato Y, Takada T, Jujo K, Minami Y, Ogihara Y, Dohi K, Fujita M, Nishikawa T, Ikeda N, Hashimoto G, Otsui K, Mori K, Sueta D, Tsubata Y, Shoji M, Shikama A, Hosoi Y, Tanabe Y, Chatani R, Tsukahara K, Nakanishi N, Kim K, Ikeda S, Mo M, Yoshikawa Y, Kimura T (2023) Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (ONCO DVT Study): an open-label, multicenter. Randomized Clinical Trial Circulation 148(21):1665–1676

CAS  PubMed  Google Scholar 

Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37-46

Article  PubMed  Google Scholar 

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M (2018) Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023

Article  CAS  PubMed  Google Scholar 

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624

Article  CAS  PubMed  Google Scholar 

Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599–1607

Article  CAS  PubMed  Google Scholar 

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 18(2):411–421

Article  CAS  PubMed  Google Scholar 

Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahé I, Pernod G, Elias A, Couturaud F, Falvo N, Sevestre MA, Ray V, Burnod A, Brebion N, Roy PM, Timar-David M, Aquilanti S, Constans J, Bura-Rivière A, Brisot D, Chatellier G, Sanchez O, Meyer G, Girard P, Mismetti P (2022) Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 161(3):781–790

Article  CAS  PubMed  Google Scholar 

Rockwood K, Theou O (2020) Using the clinical frailty scale in allocating scarce health care resources. Can Geriatr J 23(3):210–215

Article  PubMed  PubMed Central  Google Scholar 

Dauzat M, Laroche JP, Deklunder G, Ayoub J, Quére I, Lopez FM, Janbon C (1997) Diagnosis of acute lower limb deep venous thrombosis with ultrasound: trends and controversies. J Clin Ultrasound 25(7):343–358

Article  CAS  PubMed  Google Scholar 

Hisatake S, Kabuki T, Kiuchi S, Oka T, Dobashi S, Fujii T, Iwasaki Y, Ikeda T (2017) Short-term subcutaneous fondaparinux and oral edoxaban for acute venous thromboembolism. Circ J 81(6):855–861

Article  CAS  PubMed  Google Scholar 

Kabuki T, Nakanishi R, Hisatake S, Fujii T, Dobashi S, Wakakura S, Kiuchi S, Fujino T, Ikeda T (2017) A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism. J Cardiol 70(2):163–168

Article  PubMed  Google Scholar 

Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8(1):202–204

Article  CAS  PubMed  Google Scholar 

Nakamura M, Okano Y, Minamiguchi H, Munemasa M, Sonoda M, Yamada N, Hanzawa K, Aoyagi N, Tsujimoto H, Sarai N, Nakajima H, Kunieda T (2011) Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Circ J 75(6):1424–1432

Article  PubMed  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458

Article  CAS  PubMed  Google Scholar 

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruíz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL, Monreal M (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100(1):26–31